| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/20/2006 | WO2006041939A2 Use of aromatase inhibitors for endometrial thinning in preparation for surgical procedures on the endometrial cavity and uterus |
| 04/20/2006 | WO2006041930A2 Synbiotics |
| 04/20/2006 | WO2006041902A2 Use of nordihydroguaiaretic acid derivatives in the treatment of drug resistant cancer, viral and microbial infection |
| 04/20/2006 | WO2006041900A2 SUBSTITUTED N-ARYL-1H-PYRAZOLO[3,4-b]QUINOLIN-4-AMINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS |
| 04/20/2006 | WO2006041888A2 Substituted aryl or heteroarylsulfonylbutanamides for use as anti-inflammatory agents |
| 04/20/2006 | WO2006041878A2 Primary examiner |
| 04/20/2006 | WO2006041875A1 Novel prostamides for the treatment of glaucoma and related diseases |
| 04/20/2006 | WO2006041874A2 Compounds for alzheimer's disease |
| 04/20/2006 | WO2006041872A2 Thrombin receptor antagonists |
| 04/20/2006 | WO2006041855A2 Compositions and methods using apocynin compounds and nitric oxide donors |
| 04/20/2006 | WO2006041838A2 Heparinoid compositions for treatment and prevention of dementia |
| 04/20/2006 | WO2006041831A2 Cyclic β-amino acid derivatives as factor xa inhibitors |
| 04/20/2006 | WO2006041830A2 Cgrp receptor antagonists |
| 04/20/2006 | WO2006041805A1 Polyamine analogs as therapeutic agents for ocular diseases |
| 04/20/2006 | WO2006041800A2 5-phenoxyalkoxypsoralens and methods for selective inhibition of the voltage gated kv1.3 potassium channel |
| 04/20/2006 | WO2006041797A2 Acyclic hydrazides as cannabinoid receptor modulators |
| 04/20/2006 | WO2006041773A2 Lactam compounds useful as protein kinase inhibitors |
| 04/20/2006 | WO2006041769A2 Methods for the treatment of substance abuse and addiction |
| 04/20/2006 | WO2006041763A1 Renin inhibitors for treating transplantation induced diseases |
| 04/20/2006 | WO2006041636A2 Amino substituted aryloxybenzylpiperidine derivatives |
| 04/20/2006 | WO2006041613A2 Nanoparticles for targeting hepatoma cells |
| 04/20/2006 | WO2006041409A1 Medical solution, method for producing and use thereof |
| 04/20/2006 | WO2006041405A1 Substituted amino-pyrimidones and uses thereof |
| 04/20/2006 | WO2006041404A1 Substituted amino-compounds and uses thereof |
| 04/20/2006 | WO2006041204A1 Anti-graying preparation |
| 04/20/2006 | WO2006041197A1 ACTIVATOR FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR δ |
| 04/20/2006 | WO2006041158A1 Method for modifying the ambience, and spray liquid and sprayer used in the method |
| 04/20/2006 | WO2006041150A1 Preventive and/or therapeutic agent for diabetes |
| 04/20/2006 | WO2006041135A1 STAT3 PHOSPHORYLATION INHIBITOR AND Notch1 EXPRESSION INHIBITOR |
| 04/20/2006 | WO2006041121A1 Remedies/preventives for chronic skin disease |
| 04/20/2006 | WO2006041120A1 Pharmaceutical composition |
| 04/20/2006 | WO2006041119A1 Hydrazide derivatives |
| 04/20/2006 | WO2006041088A1 Brain disposition marrow progenitor |
| 04/20/2006 | WO2006041061A1 Cerebral infarction suppressant |
| 04/20/2006 | WO2006041046A1 Pyridine derivative |
| 04/20/2006 | WO2006041037A1 Novel pyridine derivative |
| 04/20/2006 | WO2006041021A1 Drug for diminishing increase of neutral fat in blood after meal and food containing the same |
| 04/20/2006 | WO2006041019A1 Process for producing 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl]-1,3-propanediol hydrochloride or hydrate thereof and intermediate for the same |
| 04/20/2006 | WO2006041015A1 Amino alcohol derivative, addition salt thereof and immunosuppressive agent |
| 04/20/2006 | WO2006040966A1 Aromatic-ring-fused pyrimidine derivative |
| 04/20/2006 | WO2006040940A1 Intestinal polyp inhibitor |
| 04/20/2006 | WO2006040914A1 Process for producing concentrate of unsaturated fatty acid |
| 04/20/2006 | WO2006040893A1 Novel antimicrobial medicine |
| 04/20/2006 | WO2006040728A1 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea as crystalline sulfate salt |
| 04/20/2006 | WO2006040680A1 Compositions and methods for intranasal, buccal, sublingual and pulmonary delivery of varenicline |
| 04/20/2006 | WO2006040676A1 Nitrosated benzopyran compounds as novel cyclooxygenase-2 selective inhibitors |
| 04/20/2006 | WO2006040672A1 Substituted cyclopropyl chromene compounds for use in the treatment and prevention of inflammation related conditions |
| 04/20/2006 | WO2006040666A1 Substituted n-alkylpyrimidinones |
| 04/20/2006 | WO2006040649A1 Crystalline forms of 3-[5-chloro-4-[(2,4-difluorobenzyl) oxy]-6-oxopyrimidin-1(6h)-yl]-n-(2-hydroxyethyl)-4-methylbenzamide |
| 04/20/2006 | WO2006040646A1 Benzimidazole or indole amides as inhibitors of pin1 |
| 04/20/2006 | WO2006040643A2 Polymorphic forms of efavirenz and processes for their preparation |
| 04/20/2006 | WO2006040625A1 Novel dipeptidyl peptidase iv inhibitors, pharmaceutical compositions containing them, and process for their preparation |
| 04/20/2006 | WO2006040615A2 Differenciation of stem cells for therapeutic use |
| 04/20/2006 | WO2006040614A1 Substituted oxazolidinone derivatives |
| 04/20/2006 | WO2006040598A2 Process for the preparation of suspension aerosol formulations, wherein the particles are formed by precipitation inside an aerosol canister |
| 04/20/2006 | WO2006040579A1 Bioactive polymers |
| 04/20/2006 | WO2006040569A1 Thiophene amide compounds for use in the treatment or prophylaxis of cancers |
| 04/20/2006 | WO2006040568A1 Quinoxalines as b raf inhibitors |
| 04/20/2006 | WO2006040558A1 Substituted adenines and the use thereof |
| 04/20/2006 | WO2006040526A1 Quinazoline derivatives for use against cancer |
| 04/20/2006 | WO2006040522A1 Quinoline derivatives |
| 04/20/2006 | WO2006040481A2 Method for diagnosing and treating crohn's disease |
| 04/20/2006 | WO2006040464A1 Method and intermediates for the preparation of derivatives of n-(1-benzhydryl-azetidin-3-yl)-n-phenyl-methylsulphonamide |
| 04/20/2006 | WO2006040451A2 Novel 9h-pyrido[2,3-b]indole derivatives serving as cdk and gsk3 inhibitors, method for the preparation thereof, and the pharmaceutical compositions containing such compounds |
| 04/20/2006 | WO2006040352A1 Novel azabicyclic aryl derivatives and their medical use |
| 04/20/2006 | WO2006040351A1 Indazoles, benzisoxazoles and benzisothiazoles and their use as estrogenic agents |
| 04/20/2006 | WO2006040349A1 Process for strengthening the barrier function of undamaged skin |
| 04/20/2006 | WO2006040338A1 Difluoro-substituted imidazopyridines |
| 04/20/2006 | WO2006040329A1 1 ibeta- hydroxysteroid dehydrogenase type 1 active spiro compounds |
| 04/20/2006 | WO2006040324A1 Composition containing omega-3 fatty acids and omega-6 fatty acids |
| 04/20/2006 | WO2006040318A2 Pi3 kinase gamma inhibitors for the treatment of anaemia |
| 04/20/2006 | WO2006040314A1 Treatment of bipolar disorders and associated symptoms |
| 04/20/2006 | WO2006040281A1 Thiazolyl-dihydro indazoles |
| 04/20/2006 | WO2006040279A1 Pi3 kinases |
| 04/20/2006 | WO2006040196A1 4-hydroxy tamoxifen gel formulations |
| 04/20/2006 | WO2006040192A1 Pyrrolidine derivatives as histamine receptors ligands |
| 04/20/2006 | WO2006040182A1 Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
| 04/20/2006 | WO2006040180A1 Aminomethyl substituted bicyclic aromatic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
| 04/20/2006 | WO2006040179A1 Aminoethylaromatic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
| 04/20/2006 | WO2006040178A1 Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to madulation of the dopamine d3 receptor |
| 04/20/2006 | WO2006040177A1 6-amino(aza)indane compounds suitable for treating disorders that respond to modulation of the dopamine d3 recptor |
| 04/20/2006 | WO2006040176A1 Azabicycloheptyl compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
| 04/20/2006 | WO2006040151A1 Subsituted hydroxyethylamine compounds for treating alzheimer’s disease |
| 04/20/2006 | WO2006040149A1 Heterocyclic ketone compounds for treating alzheimer’s disease |
| 04/20/2006 | WO2006040148A1 Tricyclic indole derivatives for use in the treatment of alzheimer’s disease |
| 04/20/2006 | WO2006040112A2 Taste-masking pharmaceutical compositions |
| 04/20/2006 | WO2006040103A1 Use of cold menthol receptor modulators for the treatment of respiratory disorders |
| 04/20/2006 | WO2006040056A1 Heterocyclic substituted bisarylurea derivatives as kinase inhibitors |
| 04/20/2006 | WO2006040052A1 1,5-naphthyridine azolidinones having cdk1 antiproliferative activity |
| 04/20/2006 | WO2006040050A1 Quinazolinylmethylene thiazolinones as cdk1 inhibitors |
| 04/20/2006 | WO2006040049A1 Novel azaindole thiazolinones as anti-cancer agents |
| 04/20/2006 | WO2006040048A1 Acidic and buffered skin-care compositions comprising nicotinamid and an absorbing agent |
| 04/20/2006 | WO2006040047A2 Diagnostics and therapeutics for diseases associated with rho/rac-interacting citron kinase (cit) |
| 04/20/2006 | WO2006040039A1 N,n'-dithenylurea derivatives used in the form of kinase inhibitors |
| 04/20/2006 | WO2006040038A1 Imidazo [1, 5-a]triazolo[1, 5-d]benzodiazepine derivatives for the treatment of cognitive disorders |
| 04/20/2006 | WO2006040036A1 Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer |
| 04/20/2006 | WO2006040004A1 Non-peptide bradykinin antagonists and pharmaceutical compositions therefrom |
| 04/20/2006 | WO2006039977A1 3-(2-hydroxyphenyl) pyrazoles and their use as hsp90 modulators |
| 04/20/2006 | WO2006039806A1 Depression of herg k+ channel function in mammalian cells and applications to the control of cancer cells division |
| 04/20/2006 | WO2006039792A1 Method of treating autoimmune diseases |